Forty-four ablations performed successfully in one patient Patient currently reportedly seizure free with improvements in mood and memory EDEN PRAIRIE, Minn., Sept. 10, 2024 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced that the OneRF Ablation System was recently used in a breakthrough patient pr ...

EDEN PRAIRIE, Minn., Aug. 12, 2024 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, will host a conference call and webcast on August 14, 2024, at 4:30 PM Eastern Time to discuss financial results for its third quarter of fiscal year 2024 ended June 30, 2024, and provide a corporate update. Conference Call and Webc ...

Contact: Specific procedure code positions OneRF™ Ablation System for broader adoption and awareness throughout the healthcare system "We are pleased that CMS has provided an ICD-10-PCS code that describes our OneRF procedure, which we believe will drive better recognition of our technology and greater utilization within the healthcare system," said Dave Rosa, CEO of NeuroOne. "In our view, CMS approval of our new code is a critical step in facilitating broader market acceptance of our technology's potentia ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 For the Quarterly Period Ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number: 001-40439 NeuroOne Medical Technologies Corporation (Exact name of Registrant as specified in its charter) Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Delaware 27- ...

Exhibit 99.1 NeuroOneReports Second Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update EDEN PRAIRIE, Minn., May 14, 2024 (GlobeNewswire) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announces its operating results for the second quarter fiscal year 2024 ended March 31, 2024. Second Quarter Fiscal Yea ...

EDEN PRAIRIE, Minn., May 10, 2024 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, will host a conference call and webcast on May 14, 2024 at 4:30 PM Eastern Time to discuss financial results for its second quarter of fiscal year 2024 ended March 31, 2024, and provide a corporate update. Conference Call and Webcast ...

EDEN PRAIRIE, Minn., May 10, 2024 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, will host a conference call and webcast on May 14, 2024 at 4:30 PM Eastern Time to discuss financial results for its second quarter of fiscal year 2024 ended March 31, 2024, and provide a corporate update. Conference Call and Webcast ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number: 001-40439 NeuroOne Medical Technologies Corporation (Exact name of Registrant as specified in its charter) Delaware ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission file number 001-40439 NeuroOne Medical Technologies Corporation (Exact name of Registrant as specified in its charter) (State or other j ...

Financial Data and Key Metrics Changes - Product revenue for Q3 2023 was $630,000, a significant increase from $32,000 in Q3 2022, and for the first nine months of fiscal 2023, product revenue reached $1.2 million compared to $102,000 in the same period of fiscal 2022 [4][16] - Collaboration revenue for the first nine months of fiscal 2023 was $1.46 million, up from $6,000 in the same period of fiscal 2022, derived from the Zimmer Development Agreement [4] - Total operating expenses in Q3 2023 were $3.8 million, compared to $2.8 million in Q3 2022, with R&D expenses at $1.9 million and SG&A expenses also at $1.9 million [4][16] - The net loss for Q3 2023 was $3.5 million, compared to a net loss of $2.8 million in the prior year period, with a total net loss of $8.7 million for the first nine months of fiscal 2023 [16] Business Line Data and Key Metrics Changes - The company has made progress with the Evo sEEG electrode limited launch, completing the targeted number of cases and training Zimmer Biomet field sales personnel [3] - The OneRF ablation system has had a 510(k) application submitted to the FDA, with expectations for commercialization in the first half of 2024 [3] Market Data and Key Metrics Changes - The company has received its first order for calendar year 2024 product supply from Zimmer Biomet, indicating positive market reception [3] Company Strategy and Development Direction - The company is evaluating direct commercialization of its devices and has ongoing discussions with strategic organizations regarding licensing technology [14] - There is a focus on developing a spinal cord stimulation program to treat chronic back pain, with successful animal testing completed [14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in addressing FDA's questions regarding the OneRF ablation system and remains optimistic about the commercialization timeline [10] - The company anticipates a reduction in operating cash burn as development costs decrease [4] Other Important Information - As of June 30, 2023, the company had cash and cash equivalents of $3.1 million, down from $8.1 million at the end of the previous fiscal year [16] - The company raised $5.2 million from a public offering and $2.5 million from an ATM program since January 2023 [16] Q&A Session Summary Question: Can you speak to the training that Zimmer has done in the field for the depth electrode alongside the ROSA robot? - Over half of Zimmer's sales force has been trained on the device, and the rollout to additional centers depends on hospital committee approvals [17] Question: How is Zimmer thinking about adding the ablation electrode to their portfolio? - There has been no pre-announcement on expected EVO sales for 2024, and the focus is on getting the device cleared through the FDA before determining the impact [19][24] Question: Can you expand on the FDA submission regarding labeling and additional information requests? - The company received fewer questions than in previous submissions, indicating a positive outlook on addressing the FDA's requests [10][26]